Cystitis-induced bladder pain is Toll-like receptor 4 dependent in a transgenic autoimmune cystitis murine model: a MAPP Research Network animal study.
Analgesics
/ pharmacology
Animals
Autoimmune Diseases
/ genetics
Cells, Cultured
Cystitis, Interstitial
/ genetics
Cytokines
/ genetics
Disease Models, Animal
Inflammation Mediators
/ metabolism
Mice, Inbred C57BL
Mice, Knockout
Nociceptive Pain
/ genetics
Ovalbumin
/ genetics
Pain Threshold
/ drug effects
Signal Transduction
Spine
/ immunology
Spleen
/ immunology
Sulfonamides
/ pharmacology
Toll-Like Receptor 4
/ antagonists & inhibitors
Urinary Bladder
/ drug effects
Urodynamics
Multidisciplinary Approach to the Study of Chronic Pelvic Pain
Toll-like receptor 4
cystitis
model
pain
Journal
American journal of physiology. Renal physiology
ISSN: 1522-1466
Titre abrégé: Am J Physiol Renal Physiol
Pays: United States
ID NLM: 100901990
Informations de publication
Date de publication:
01 07 2019
01 07 2019
Historique:
pubmed:
16
5
2019
medline:
17
3
2020
entrez:
16
5
2019
Statut:
ppublish
Résumé
Altered Toll-like receptor (TLR)4 activation has been identified in several chronic pain conditions but has not been well studied in interstitial cystitis/bladder pain syndrome (IC/BPS). Our previously published human studies indicated that patients with IC/BPS present altered systemic TLR4-mediated inflammatory responses, which were significantly correlated with reported pain severity. In the present study, we sought to determine whether altered TLR4 activation plays a role in pelvic/bladder pain seen in patients with IC/BPS using our validated IC/BPS-like transgenic autoimmune cystitis model (URO-OVA). URO-OVA mice developed responses consistent with pelvic and bladder pain after cystitis induction, which was associated with increased splenocyte production of TLR4-mediated proinflammatory cytokines IL-1β, IL-6, and TNF-α. Increased spinal expression of mRNAs for proinflammatory cytokines IL-6 and TNF-α, glial activation markers CD11b and glial fibrillary acidic protein, and endogenous TLR4 ligand high mobility group box 1 was also observed after cystitis induction. Compared with URO-OVA mice, TLR4-deficient URO-OVA mice developed significantly reduced nociceptive responses, although similar bladder inflammation and voiding dysfunction, after cystitis induction. Intravenous administration of TAK-242 (a TLR4-selective antagonist) significantly attenuated nociceptive responses in cystitis-induced URO-OVA mice, which was associated with reduced splenocyte production of TLR4-mediated IL-1β, IL-6, and TNF-α as well as reduced spinal expression of mRNAs for IL-6, TNF-α, CD11b, glial fibrillary acidic protein, and high mobility group box 1. Our results indicate that altered TLR4 activation plays a critical role in bladder nociception independent of inflammation and voiding dysfunction in the URO-OVA model, providing a potential mechanistic insight and therapeutic target for IC/BPS pain.
Identifiants
pubmed: 31091120
doi: 10.1152/ajprenal.00017.2019
pmc: PMC6692719
doi:
Substances chimiques
Analgesics
0
Cytokines
0
Inflammation Mediators
0
Sulfonamides
0
Tlr4 protein, mouse
0
Toll-Like Receptor 4
0
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate
0
Ovalbumin
9006-59-1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
F90-F98Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK111396
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK082325
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK082344
Pays : United States
Références
Urol Res. 1999 Oct;27(5):351-6
pubmed: 10550523
Immunol Cell Biol. 2000 Apr;78(2):110-7
pubmed: 10762410
J Urol. 2000 Aug;164(2):423-7
pubmed: 10893601
Neurochem Res. 2000 Oct;25(9-10):1439-51
pubmed: 11059815
J Immunol. 2002 May 1;168(9):4701-10
pubmed: 11971020
Scand J Urol Nephrol. 2003;37(1):60-3
pubmed: 12745747
J Urol. 1992 Dec;148(6):1951-6
pubmed: 1433651
Int J Urol. 2003 Oct;10 Suppl:S35-8
pubmed: 14641413
J Urol. 2004 Apr;171(4):1704-8
pubmed: 15017270
J Urol. 2005 Aug;174(2):576-80
pubmed: 16006901
Mol Pharmacol. 2006 Apr;69(4):1288-95
pubmed: 16373689
J Immunol. 2007 Jan 1;178(1):539-46
pubmed: 17182594
PLoS Pathog. 2007 Apr;3(4):e60
pubmed: 17465679
BJU Int. 2007 Sep;100(3):664-7
pubmed: 17550411
Eur J Pharmacol. 2007 Oct 1;571(2-3):231-9
pubmed: 17632100
Nat Clin Pract Urol. 2007 Sep;4(9):484-91
pubmed: 17823601
J Autoimmun. 2008 Jun;30(4):257-65
pubmed: 18162370
PLoS One. 2008 May 07;3(5):e2096
pubmed: 18461160
BJU Int. 2008 Dec;102(11):1724-30
pubmed: 18710451
J Neurochem. 2010 Jul;114(1):13-27
pubmed: 20402965
Crit Care Med. 2010 Aug;38(8):1685-94
pubmed: 20562702
J Biomed Biotechnol. 2011;2011:937061
pubmed: 21113298
Physiol Rev. 2011 Apr;91(2):461-553
pubmed: 21527731
Eur Urol. 2012 Jan;61(1):193-200
pubmed: 21719190
Exp Neurol. 2012 Apr;234(2):316-29
pubmed: 22001158
Stroke. 2013 Sep;44(9):2545-52
pubmed: 23839500
J Pharmacol Sci. 2013;123(4):301-5
pubmed: 24285082
J Urol. 2014 May;191(5):1294-9
pubmed: 24316091
Biol Psychiatry. 2014 Aug 15;76(4):340-8
pubmed: 24331544
J Neuroinflammation. 2014 Jan 11;11:8
pubmed: 24410883
Mol Med. 2014 Mar 24;20:138-46
pubmed: 24531836
Eur J Pain. 2014 Nov;18(10):1480-9
pubmed: 24756904
Pain. 2014 Sep;155(9):1755-61
pubmed: 24907404
Pain. 2014 Sep;155(9):1802-13
pubmed: 24954167
J Urol. 2015 Jan;193(1):138-44
pubmed: 25092637
Am J Physiol Renal Physiol. 2015 Jan 15;308(2):F103-13
pubmed: 25209862
Mol Med. 2015 Feb 05;20:569-78
pubmed: 25222915
J Urol. 2015 May;193(5):1545-53
pubmed: 25623737
Brain Behav Immun. 2015 Oct;49:66-74
pubmed: 25771510
Urology. 2015 Jun;85(6):1454-65
pubmed: 26099889
Int J Clin Exp Med. 2015 Jul 15;8(7):11202-7
pubmed: 26379924
Urology. 2016 Apr;90:56-61
pubmed: 26768711
Brain Behav Immun. 2016 Aug;56:271-80
pubmed: 27044335
PLoS One. 2016 Sep 29;11(9):e0163829
pubmed: 27684718
PLoS One. 2016 Dec 21;11(12):e0168772
pubmed: 28002455
BJU Int. 2017 Jul;120(1):130-142
pubmed: 28263447
BJU Int. 2017 Oct;120(4):576-583
pubmed: 28581681
Mol Med Rep. 2017 Oct;16(4):3863-3868
pubmed: 28765897
Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F460-F468
pubmed: 29717937
Urol Res. 1996;24(6):367-73
pubmed: 9008331